Screener
Ligand Pharmaceuticals LGND Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
FAQ
- What is Ligand Pharmaceuticals's cash & equivalents?
- Ligand Pharmaceuticals (LGND) reported cash & equivalents of $1.01B in Q2 2026.
- How has Ligand Pharmaceuticals's cash & equivalents changed year-over-year?
- Ligand Pharmaceuticals's cash & equivalents increased by 1387.7% year-over-year, from $67.67M to $1.01B.
- What is the long-term trend for Ligand Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's cash & equivalents has grown at a 29.5% compound annual growth rate (CAGR), from $47.96M to $174.93M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Ligand Pharmaceuticals's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude